REG - Cizzle Biotechnology - Appointment of Professor Dawn Coverley as CSO

Cizzle Biotechnology HoldingsAnnouncement

02/01/2025 07:00

For best results when printing this announcement, please click on link below:
https://newsfile.refinitiv.com/getnewsfile/v1/story?guid=urn:newsml:reuters.com:20250102:nRSB8193Ra&default-theme=true

RNS Number : 8193R  Cizzle Biotechnology Holdings PLC  02 January 2025

THIS ANNOUNCEMENT CONTAINS INSIDE INFORMATION FOR THE PURPOSES OF ARTICLE 7 OF
EU REGULATION 596/2014 (WHICH FORMS PART OF DOMESTIC UK LAW PURSUANT TO THE
EUROPEAN UNION (WITHDRAWAL) ACT 2018 ("EUWA")) ("UK MAR").

2 January 2025

Cizzle Biotechnology Holdings plc

 

("Cizzle", "Cizzle Biotechnology", or the "Company")

 

Appointment of Professor Dawn Coverley as Chief Scientific Officer

Update on Launch of CIZ1B Biomarker Assay

To directly support and accelerate the Company's global licensing and
partnership strategy to bring its non-invasive, cost effective, CIZ1B
biomarker lung cancer blood test to market in 2025, Cizzle Biotechnology, the
UK based diagnostics developer, is pleased to announce that Professor Dawn
Coverley, Founder and Non-Executive Director ("NED") of Cizzle Biotechnology
has, with immediate effect, been appointed Chief Scientific Officer ("CSO"),
an executive role on the board of the Company.

 

Key Highlights

 

·    Professor Dawn Coverley has been appointed CSO with immediate effect.
 Her new role is an executive role on the Company's board and replaces her
current position as an NED.

 

·    Successful completion of a technical programme to launch the most
cost-effective and scalable version of the CIZ1B biomarker assay as an ELISA
(Enzyme-Linked Immunosorbent Assay) for CLIA accreditation.

 

The change in role from NED to CSO, enables Dawn to allocate more of her
expert time to directly support the Company's licensing partners, particularly
in the USA, to support Cizzle Bio Inc's CAP (College of American Pathologists)
accredited laboratory partners, helping them to achieve CLIA (Clinical
Laboratory Improvement Amendments) LDT (Laboratory Developed Test)
accreditation and identify and lead new non-dilutive grant funded research and
clinical evaluations.

 

Dawn is currently a professor and principal investigator of a research
laboratory at the University of York, studying how specialised cells are
protected from age-related decay. After a first degree in Genetics
(Leicester), and a PhD in Biochemistry (Cancer Research UK), she completed
postdoctoral training at the University of Cambridge, then moved to the
University of York to establish an independent research group in 2002,
supported by the Lister Institute of Preventive Medicine.

 

Dawn will reduce a number of her current teaching and scientific roles at the
University of York in order to devote sufficient time to the Company's
activities, whilst maintaining a number of key roles, including leadership of
her research group and management of the Company's existing research and
development contract at the University of York.

 

The timing of this appointment coincides with the successful completion of the
technical programme which confirms that the most cost-effective and scalable
version of the CIZ1B biomarker assay for CLIA accreditation is an ELISA. The
rigorous quality control programme undertaken has been able to demonstrate
equivalence with initial manual laboratory tests and with the BioTechne
ProteinSimple capillary Western system. Results have shown sensitivity
equivalent to published CIZ1B lung cancer studies *, and an ability to
correctly identify people with lung cancer with few false negative results.
This is another major step in demonstrating that the Company's lung cancer
blood test is both cost effective and a commercially scalable global solution
to reduce premature cancer deaths and improve survival rates and quality of
life for cancer patients.

 

Commenting, Allan Syms, Executive Chairman of Cizzle Biotechnology, said:

 

"I am delighted that Dawn will be able to allocate more of her time to
directly support the Company as we progress through the commercial phase and
the test is rolled out to partner laboratories. As the founder of Cizzle and
the world expert on the CIZ1 gene and our CIZ1B variant biomarker, Dawn will
be able to take a greater role in the direction and implementation of our
entire research and development programme, managing Cizzle's participation in
clinical evaluations with cancer centres across the globe and directly
supporting the Company's licensing partners' route to market. We are extremely
grateful to the University of York for accommodating this change in her role
which will enable her to continue as head of her research group, and in
delivering our important research agreement with the University."

 

* Variant Ciz1 is a circulating biomarker for early-stage lung cancer
(https://pubmed.ncbi.nlm.nih.gov/23074256/) PNAS USA
(https://pubmed.ncbi.nlm.nih.gov/23074256/) 2012
(https://pubmed.ncbi.nlm.nih.gov/23074256/) and A quantitative immunoassay for
lung cancer biomarker CIZ1b in patient plasma
(https://pubmed.ncbi.nlm.nih.gov/27867087/) Clin Biochem.
(https://pubmed.ncbi.nlm.nih.gov/27867087/) 2017
(https://pubmed.ncbi.nlm.nih.gov/27867087/)

Enquiries:

 

 Cizzle Biotechnology Holdings plc  Via IFC Advisory
 Allan Syms (Executive Chairman)

 

 Allenby Capital Limited                                     +44(0) 20 3328 5656
 John Depasquale/George Payne (Corporate Finance)
 Stefano Aquilino/Amrit Nahal (Sales and Corporate Broking)

 

 IFC Advisory Limited            +44(0) 20 3934 6630
 Tim Metcalfe
 Florence Chandler

 

About Cizzle Biotechnology

Based on the pioneering work of Professor Coverley and colleagues, on a
naturally occurring variant of the cell nuclear protein CIZ1, the CIZ1B
biomarker is highly associated with the presence of early-stage cancer. The
company has developed CIZ1B into a non-invasive, cost-effective blood test to
help in the early detection of lung cancer and has now entered into commercial
royalty-bearing arrangements to license its proprietary technology, and into
collaborations with centres of excellence in cancer care.  Cizzle was
admitted to the Standard segment of the main market of the London Stock
Exchange in May 2021.

 

For more information, please see https://cizzlebiotechnology.com
(https://cizzlebiotechnology.com)

You can also follow the Company through its twitter account @CizzlePlc and on
LinkedIn.

 

 

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact
rns@lseg.com (mailto:rns@lseg.com)
 or visit
www.rns.com (http://www.rns.com/)
.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our
Privacy Policy (https://www.lseg.com/privacy-and-cookie-policy)
.   END  MSCBFLFBEFLEBBD